In section Market Quotes

HLS Therapeutics Targets 1.5 Million Shares in Buyback Plan

Toronto-based HLS Therapeutics will initiate a normal course issuer bid to repurchase up to 8% of its public float, following approval from the Toronto Stock Exchange. The pharmaceutical company aims to cancel 1.5 million shares, an effort to stabilize stock value after a period of downward pressure on its equity.

By Money Talk·June 23, 2026·2 min read·409 reads

HLS Therapeutics Targets 1.5 Million Shares in Buyback Plan

The buyback program, valued at approximately 6.7 million Canadian dollars based on Monday’s closing price, is scheduled to commence on June 25. HLS Therapeutics has set a one-year window to complete these repurchases.

This move comes as the company faces a challenging market climate, with share prices sliding 7.3% to settle at 4.47 Canadian dollars by the end of Monday’s session. By reducing its total outstanding shares, the company seeks to manage its capital structure amid ongoing market volatility.

HLS Therapeutics Targets 1.5 Million Shares in Buyback Plan

Comments (0)